TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

  • STATUS
    Recruiting
  • participants needed
    50
  • sponsor
    Rutgers, The State University of New Jersey
Send
Updated on 16 February 2024
See if I qualify
cancer
absolute neutrophil count
measurable disease
neutrophil count
chemotherapy regimen
oxaliplatin
irinotecan
bevacizumab
tumor cells
carcinoma
fluorouracil
cancer chemotherapy
colon cancer
adjuvant therapy
adjuvant chemotherapy
colon carcinoma
ras mutation
tas-102
enteral tube feeding
recurrent colorectal cancer
trifluridine and tipiracil hydrochloride
adjuvant
colorectal cancer
EGFR
stage iv colon cancer
recurrent colon cancer
stage ivb colon cancer
stage iva colon cancer

Summary

This phase II trial studies how well TAS-102 and oxaliplatin work in treating patients with stage IV colon cancer. Drugs used in chemotherapy, such as TAS-102 and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Description

PRIMARY OBJECTIVE:

I. Overall response rate (ORR).

SECONDARY OBJECTIVES:

I. Progression free survival (PFS). II. Overall survival (OS). III. Disease control rate (DCR). IV. Duration of response. V. Safety and tolerability.

OUTLINE

Patients receive trifluridine and tipiracil hydrochloride (TAS-102) orally (PO) twice daily (BID) on days 1-5 and oxaliplatin intravenously (IV) over 2 hours on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 28 days.

Details
Condition Metastatic Colorectal Carcinoma, Recurrent Colon Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colon Cancer AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7
Age 18years - 100years
Treatment Oxaliplatin, Trifluridine and Tipiracil Hydrochloride
Clinical Study IdentifierNCT04294264
SponsorRutgers, The State University of New Jersey
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Histologically confirmed stage IV colon cancer (American Joint Committee on Cancer [AJCC] 7th edition) that has progressed after standard therapy that included fluorouracil (5-FU), irinotecan, oxaliplatin, bevacizumab (unless contraindicated) and an anti-EGFR antibody, if RAS wild type. Patients who could not tolerate standard agents because of unacceptable, but reversible toxicity necessitating their discontinuation will be allowed to participate
Patients who had received adjuvant chemotherapy and had recurrence during or within 6 months of completion of the adjuvant chemotherapy will be allowed to count the adjuvant therapy as one chemotherapy regimen
Progression of disease must be documented on the most recent scan
Presence of measurable disease
RAS mutation and mismatch repair deficiency (MMR) status must be determined (or tissue availability for testing if not already determined)
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Life expectancy of at least 3 months
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
Hemoglobin >= 9 g/dL
Platelets (PLT) >= 75 x 10^9/L
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x upper limit of normal (ULN)
Adequate contraception if applicable
Women who are nursing and discontinue nursing prior to enrollment in the program
Ability to take oral medication (i.e., no feeding tube)
Patient able and willing to comply with study procedures as per protocol
Patient able to understand and willing to sign and date the written voluntary informed consent form (ICF) at screening visit prior to any protocol-specific procedures

Exclusion Criteria

Patients who have previously received TAS-102
Grade 2 or higher peripheral neuropathy (functional impairment)
Symptomatic central nervous system (CNS) metastases requiring treatment
Other active malignancy within the last 3 years (except for non-melanoma skin cancer or a non-invasive/in situ cancer)
Pregnancy or breast feeding
Current therapy with other investigational agents
Active infection with body temperature >= 38 degree Celsius (C) due to infection
Major surgery within prior 4 weeks (the surgical incision should be fully healed prior to drug administration)
Any anticancer therapy within prior 3 weeks of first dose of study drug
History of allergic reactions attributed to compounds of similar chemical or biologic composition to TAS-102
Current therapy with other investigational agents or participation in another clinical study or any investigational agent received within prior 4 weeks
Grade 3 or higher hypersensitivity reaction to oxaliplatin, or grade 1-2 hypersensitivity reaction to oxaliplatin not controlled with pre-medication
Has unresolved toxicity of greater than or equal to Common Terminology Criteria for Adverse (CTCAE) grade 2 attributed to any prior therapies (excluding anemia, alopecia, skin pigmentation, and platinum-induced neurotoxicity)
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer
absolute neutrophil count
measurable disease
neutrophil count
chemotherapy regimen
oxaliplatin
irinotecan
bevacizumab
tumor cells
carcinoma
fluorouracil
cancer chemotherapy
colon cancer
adjuvant therapy
adjuvant chemotherapy
colon carcinoma
ras mutation
tas-102
enteral tube feeding
recurrent colorectal cancer
trifluridine and tipiracil hydrochloride
adjuvant
colorectal cancer
EGFR
stage iv colon cancer
recurrent colon cancer
stage ivb colon cancer
stage iva colon cancer

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.